Yatsen has participated in a series A-plus round for the diversified drug developer, six months after its closed a $60m series A.

Diversified China-based therapeutics developer MingMed Biotechnology secured $50m yesterday in a series A-plus round that included beauty e-commerce platform operator Yatsen Holding.

Jifeng Ventures, Yifeng Capital, Oceanpine Capital, Gaorong Capital, JCP Capital and Flower City Ventures filled out the participants in the round.

Founded in 2019, MingMed Biotechnology is developing small-molecule cancer therapies in addition to drugs for use in cosmetic procedures and the treatment of ocular disorders.

Gaorong Capital led the company’s $60m series A round in March this…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Edison Fu

Edison Fu is a reporter and Asia liaison at Global Corporate Venturing.
Email LinkedIn